Your browser doesn't support javascript.
loading
Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis.
Zhu, Chao; Zhou, Zhen; Roos, Izanne; Merlo, Daniel; Kalincik, Tomas; Ozakbas, Serkan; Skibina, Olga; Kuhle, Jens; Hodgkinson, Suzanne; Boz, Cavit; Alroughani, Raed; Lechner-Scott, Jeannette; Barnett, Michael; Izquierdo, Guillermo; Prat, Alexandre; Horakova, Dana; Kubala Havrdova, Eva; Macdonell, Richard; Patti, Francesco; Khoury, Samia Joseph; Slee, Mark; Karabudak, Rana; Onofrj, Marco; Van Pesch, Vincent; Prevost, Julie; Monif, Mastura; Jokubaitis, Vilija; van der Walt, Anneke; Butzkueven, Helmut.
Affiliation
  • Zhu C; Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia Chao.Zhu@monash.edu.
  • Zhou Z; Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia.
  • Roos I; Clinical Outcomes Research Unit, Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia.
  • Merlo D; Department of Neurology, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
  • Kalincik T; Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia.
  • Ozakbas S; Clinical Outcomes Research Unit, Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia.
  • Skibina O; Department of Neurology, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
  • Kuhle J; Dokuz Eylul University, Izmir, Turkey.
  • Hodgkinson S; Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia.
  • Boz C; Department of Neurology, Alfred Hospital, Melbourne, Victoria, Australia.
  • Alroughani R; Neurologic Clinic and Policlinic, Departments of Medicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.
  • Lechner-Scott J; Departments of Nephrology and Neurology, Liverpool Hospital, Sydney, New South Wales, Australia.
  • Barnett M; KTU Medical Faculty Farabi Hospital, Trabzon, Turkey.
  • Izquierdo G; Division of Neurology, Amiri Hospital, Sharq, Kuwait.
  • Prat A; Department of Neurology, John Hunter Hospital, Newcastle, New South Wales, Australia.
  • Horakova D; School of Medicine and Public Health, University Newcastle, Newcastle, New South Wales, Australia.
  • Kubala Havrdova E; Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.
  • Macdonell R; Hospital Universitario Virgen Macarena, Sevilla, Spain.
  • Patti F; Hôpital Notre Dame, CHUM and Universite de Montreal, Montreal, Québec, Canada.
  • Khoury SJ; Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic.
  • Slee M; Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic.
  • Karabudak R; Austin Health, Melbourne, Victoria, Australia.
  • Onofrj M; Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, Catania, Italy.
  • Van Pesch V; Multiple Sclerosis Center, University of Catania, Catania, Italy.
  • Prevost J; Nehme and Therese Tohme Multiple Sclerosis Center, American University of Beirut Medical Center, Beirut, Lebanon.
  • Monif M; Flinders University, Adelaide, South Australia, Australia.
  • Jokubaitis V; Department of Neurology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
  • van der Walt A; Department of Neuroscience, Imaging, and Clinical Sciences, University G. d'Annunzio, Chieti, Italy.
  • Butzkueven H; Cliniques Universitaires Saint-Luc, Brussels, Belgium.
J Neurol Neurosurg Psychiatry ; 93(12): 1330-1337, 2022 12.
Article in En | MEDLINE | ID: mdl-36261289
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Multiple Sclerosis, Relapsing-Remitting / Multiple Sclerosis Type of study: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limits: Humans Language: En Journal: J Neurol Neurosurg Psychiatry Year: 2022 Type: Article Affiliation country: Australia
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Multiple Sclerosis, Relapsing-Remitting / Multiple Sclerosis Type of study: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limits: Humans Language: En Journal: J Neurol Neurosurg Psychiatry Year: 2022 Type: Article Affiliation country: Australia